Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Company Overview

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran). These medicines are used to treat rare diseases including hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1. Amvuttra is also approved for certain forms of transthyretin amyloidosis, including disease affecting the heart.

The company continues to develop RNAi-based treatments for diseases in areas such as genetic disorders, cardiometabolic conditions, central nervous system diseases and liver-related conditions. Alnylam serves patients and healthcare markets internationally through its commercial operations, regulatory approvals and partnerships with other pharmaceutical companies.

Key Stats

• Today's Range: $246.01 to $254.08
• 50-Day Range: $205.48 to $323.50
• 52-Week Range: $197.81 to $495.55
• Volume: 1.18 million shs
• Average Volume: 1.66 million shs
• Market Capitalization: $33.28 billion
• P/E Ratio: 46.22
• Dividend Yield: N/A
• Price Target: $376.67
• Consensus Rating: Moderate Buy

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

Alnylam Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 51st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 17 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Alnylam Pharmaceuticals has a consensus price target of $376.67, representing about 51.5% upside from its current price of $248.68.

Amount of Analyst Coverage

Alnylam Pharmaceuticals has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 44.56%

Earnings Growth

Earnings for Alnylam Pharmaceuticals are expected to grow by 44.56% in the coming year, from $6.71 to $9.70 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alnylam Pharmaceuticals is 46.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alnylam Pharmaceuticals is 46.22, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.98.

Price to Book Value per Share Ratio

Alnylam Pharmaceuticals has a P/B Ratio of 41.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.78% of the float of Alnylam Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alnylam Pharmaceuticals has recently increased by 32.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alnylam Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Alnylam Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.12

News Sentiment

Alnylam Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Alnylam Pharmaceuticals this week, compared to 11 articles on an average week.

Search Interest

Only 9 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

MarketBeat Follows

Only 9 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.86% of the stock of Alnylam Pharmaceuticals is held by insiders.

Percentage Held by Institutions

92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/11/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Investor update: 9/17/2026
• Investor update: 10/26/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALNY
• CIK: 1178670
• Web: www.alnylam.com
• Phone: (617) 551-8200
• Fax: 617-551-8101
• Employees: 2,770
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Alnylam Pharmaceuticals: $376.67
• High Price Target: $566.00
• Low Price Target: $256.00
• Potential Upside/Downside: +51.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.38
• Trailing P/E Ratio: 46.22
• Forward P/E Ratio: 37.06
• P/E Growth: N/A
• Net Income: $313.75 million
• Net Margins: 15.26%
• Pretax Margin: 15.95%
• Return on Equity: 84.93%
• Return on Assets: 14.30%

Debt

• Debt-to-Equity Ratio: 0.75
• Current Ratio: 3.05
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $3.71 billion
• Price / Sales: 8.96
• Cash Flow: $2.81 per share
• Price / Cash Flow: 88.52
• Book Value: $5.97 per share
• Price / Book: 41.65

Miscellaneous

• Outstanding Shares: 133,810,000
• Free Float: 132,658,000
• Market Cap: $33.28 billion
• Optionable: Optionable
• Beta: 0.31